Alendronate Inhibits VEGF Expression in Growth Plate Chondrocytes by Acting on the Mevalonate Pathway

Table 1: VEGF Protein (pg/ml), Adjusted for Total Protein, Secreted into the Media or Cell Associated from Murine Endochondral Chondrocytes Treated with Alendronate (ALN) and Mevalonate Intermediates Farnesol (FOH) and Geranylgeraniol (GGOH) for 72 h

Media VEGF Protein	Control	ALN	ALN + FOH	ALN + GGOH
10µM ALN	306.9 ± 4.6^a	207.2 ± 4.6^b	132.0 ± 4.6^c	196.3 ± 4.6^b
100µM ALN	279.5 ± 4.6^a	137.8 ± 4.6^c	239.4 ± 4.6^b	105.7 ± 4.6^c
Cell VEGF Protein
10µM ALN	19.5 ± 1.9^a	34.8 ± 1.9^b	26.4 ± 1.9^a	36.4 ± 1.9^b
100µM ALN	18.6 ± 1.9^a	19.4 ± 1.9^a	9.7 ± 1.9^b	12.4 ± 1.9^b

Values expressed as LSMEANS ± SEM. Different superscripts within ALN dose (row) indicate means differ (p < 0.001); n = 6 for each different treatment group within a row.